Congress 115 - HR 5782 - Opioid Crisis Accountability Act of 2018

Sponsor

Cosponsors

Topics

Business ethics Business expenses Business records Child health Civil actions and liability Corporate finance and management Department of Health and Human Services Department of Justice Department of Labor Drug safety, medical device, and laboratory regulation Drug trafficking and controlled substances Drug, alcohol, tobacco use Education programs funding Elementary and secondary education Employment taxes Executive agency funding and structure Government information and archives Government studies and investigations Government trust funds Health Health programs administration and funding Health promotion and preventive care Income tax credits Marketing and advertising Medical research Preschool education Prescription drugs Research and development Securities Small business Wages and earnings

Full Text

View Full Bill Text

Votes

Summary

Opioid Crisis Accountability Act of 2018

This bill amends the Federal Food, Drug, and Cosmetic Act to prohibit a drug manufacturer from engaging in illegal marketing and distribution practices, including falsely advertising, promoting, or marketing that an opioid has no addiction-forming or addiction-sustaining qualities or risks, supplying states or communities with a quantity of opioids that is not medically necessary, or failing to report any order or pattern of orders that would cause a reasonable person to believe the opioids were not being dispensed in a medically reasonable manner.

Actions

May 31, 2018

Referred to the Subcommittee on Health.
May 11, 2018

Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and the Workforce, Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
May 11, 2018

Introduced in House

Amendments

Related Bills